Eyepoint sells $100M in shares after unveiling eye disease data for drug-device asset

EyePoint Pharmaceuticals is selling $100 million worth of shares on the back of positive mid-stage data for a drug-device candidate in diabetic macular edema. The results pushed its share price up by as much as ...